Edwin J. C. G. van Den Oord
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edwin J. C. G. van Den Oord has a total of 395 co-authors. Here are the top co-authors by number of shared publications:
- Karolina A. Aberg
Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA, USA
29 shared publications - Robin F. Chan
Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA, USA
11 shared publications Min Zhao
Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, USA
9 shared publications- Joseph L. McClay
Virginia Commonwealth University
7 shared publications - Shaunna L. Clark
Texas A&M University
7 shared publications Andrey A. Shabalin
Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, Virginia
6 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Springer Nature in Nature Mental Health
A large-scale meta-analysis of DNA methylation signatures of alcohol use disorder in the Psychiatric Genomics Consortium
Despite extensive research on DNA methylation signatures associated with alcohol use disorder (AUD), findings are often inconsistent. Here we conducted a large-scale meta-analysis of epigenome-wide association studies (EWASs) to identify reliable, reproducible epigenetic markers of AUD. Seven cohorts, comprising 3,775 individuals (1,325 with AUD), contributed to this meta-analysis. Downstream analyses included differentially methylated regions, overrepresentation analyses and the construction of a methylation risk score. We identified 118 significant CpG sites associated with AUD, with the strongest association found at cg24889777 ( P = 5.12 × 10 −17 ). CpG sites were enriched for pathways related to GTPase signaling, transmembrane transporter activity and EWAS signals of alcohol consumption. The methylation risk score explained 2.06% of the variance in alcohol consumption and predicted heavy drinking in an independent cohort ( N = 2,534, area under the curve = 0.657). This analysis offers key insights into the epigenetic mechanisms of AUD and lays the groundwork for future research on methylation risk scores for the diagnosis, prognosis and treatment of AUD.
- 29 June 2026
- Published by Springer Nature in Nature Mental Health
Open AccessA large-scale meta-analysis of DNA methylation signatures of alcohol use disorder in the Psychiatric Genomics Consortium
Despite extensive research on DNA methylation signatures associated with alcohol use disorder (AUD), findings are often inconsistent. Here we conducted a large-scale meta-analysis of epigenome-wide association studies (EWASs) to identify reliable, reproducible epigenetic markers of AUD. Seven cohorts, comprising 3,775 individuals (1,325 with AUD), contributed to this meta-analysis. Downstream analyses included differentially methylated regions, overrepresentation analyses and the construction of a methylation risk score. We identified 118 significant CpG sites associated with AUD, with the strongest association found at cg24889777 ( P = 5.12 × 10 −17 ). CpG sites were enriched for pathways related to GTPase signaling, transmembrane transporter activity and EWAS signals of alcohol consumption. The methylation risk score explained 2.06% of the variance in alcohol consumption and predicted heavy drinking in an independent cohort ( N = 2,534, area under the curve = 0.657). This analysis offers key insights into the epigenetic mechanisms of AUD and lays the groundwork for future research on methylation risk scores for the diagnosis, prognosis and treatment of AUD.
- Open Access
- 1 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Methylome-wide association study in blood suggests cell type-specific relationships between DNA methylation and lifetime anxiety
Anxiety disorders are prevalent and can greatly impact well-being. The biological mechanisms behind anxiety are not fully understood, but growing evidence suggests a role for DNA methylation. Here, we conduct a large-scale methylome-wide association study of lifetime anxiety in 14,443 participants (1817 cases and 12,626 controls) in whole blood, and, through epigenomic deconvolution, 12 different blood cell types. We detect four CpG associations at methylome-wide significance in whole blood, and a range between 15 and 124 associations among the cell types. Top cell type-specific findings include genes potentially involved in stress response such as FAM171A2 and VIPAS39 and genes that have been previously linked to anxiety, such as NCOR1. Whole blood and all cell type-specific findings significantly overlap with findings from two previous methylome-wide association studies of lifetime anxiety and an anxiety GWAS, suggesting results are robust. Pathway analyses broadly implicate anxiety-related impacts on cellular stress response. Analyses of five epigenetic clocks suggest DNA methylation-based phenotypic aging and pace of aging may be accelerated in anxiety. Our results support a cell type-specific relationship between DNA methylation and anxiety and highlight the utility of including cell type-specific analyses in whole blood studies of DNA methylation.
- 1 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMethylome-wide association study in blood suggests cell type-specific relationships between DNA methylation and lifetime anxiety
Anxiety disorders are prevalent and can greatly impact well-being. The biological mechanisms behind anxiety are not fully understood, but growing evidence suggests a role for DNA methylation. Here, we conduct a large-scale methylome-wide association study of lifetime anxiety in 14,443 participants (1817 cases and 12,626 controls) in whole blood, and, through epigenomic deconvolution, 12 different blood cell types. We detect four CpG associations at methylome-wide significance in whole blood, and a range between 15 and 124 associations among the cell types. Top cell type-specific findings include genes potentially involved in stress response such as FAM171A2 and VIPAS39 and genes that have been previously linked to anxiety, such as NCOR1. Whole blood and all cell type-specific findings significantly overlap with findings from two previous methylome-wide association studies of lifetime anxiety and an anxiety GWAS, suggesting results are robust. Pathway analyses broadly implicate anxiety-related impacts on cellular stress response. Analyses of five epigenetic clocks suggest DNA methylation-based phenotypic aging and pace of aging may be accelerated in anxiety. Our results support a cell type-specific relationship between DNA methylation and anxiety and highlight the utility of including cell type-specific analyses in whole blood studies of DNA methylation.
- Open Access
- 16 February 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (6) , 3506-3515
A large-scale DNA methylation study of alcohol use identified robust associations and cell-type specific insights
The biological mechanisms linking alcohol consumption to health outcomes are not fully understood, but growing evidence suggests a role for DNA methylation (DNAm). In this study, we conducted the largest and most comprehensive methylome-wide association study (MWAS) of alcohol using a cohort of 13,970 participants and, through epigenomic deconvolution, investigated cell-type specific associations in 12 different blood cell-types. We then replicated our whole blood findings using summary statistics from an existing alcohol MWAS and characterized our findings using bioinformatic analyses. We identified 1,266 methylome-wide significant (p < 9.42×10-08) findings in whole blood. Fewer significant associations were found in the cell-types: 8 in both neutrophils and CD8+ naïve T-cells, 3 in both CD8+ memory T-cells and eosinophils, and 1 in T regulatory cells. The top replicating finding in whole blood was in SLC7A11 (p = 1.19×10-150) and was previously implicated in other alcohol MWASs. In the cell-type specific results, the top finding was in PDIA5 in CD8+ naïve T-cells (p = 2.83×10-12). Whole blood and cell-type specific findings tended to show significant overlap with genome-wide association studies of problematic alcohol use but not those based on alcohol consumption. In summary, we observed considerable overlap with previous alcohol MWASs and GWASs suggesting robust associations. Further, our novel DNAm findings, such as the involvement of Rho GTPase pathways, implicate new therapeutic targets that warrant further investigation. Due to the large number of findings in whole blood and coordinated changes across cell-types, we hypothesize results may capture alcohol exposure effects. Future work should use novel design to disentangle exposure versus liability effects.
- 16 February 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (6) , 3506-3515
Open AccessA large-scale DNA methylation study of alcohol use identified robust associations and cell-type specific insights
The biological mechanisms linking alcohol consumption to health outcomes are not fully understood, but growing evidence suggests a role for DNA methylation (DNAm). In this study, we conducted the largest and most comprehensive methylome-wide association study (MWAS) of alcohol using a cohort of 13,970 participants and, through epigenomic deconvolution, investigated cell-type specific associations in 12 different blood cell-types. We then replicated our whole blood findings using summary statistics from an existing alcohol MWAS and characterized our findings using bioinformatic analyses. We identified 1,266 methylome-wide significant (p < 9.42×10-08) findings in whole blood. Fewer significant associations were found in the cell-types: 8 in both neutrophils and CD8+ naïve T-cells, 3 in both CD8+ memory T-cells and eosinophils, and 1 in T regulatory cells. The top replicating finding in whole blood was in SLC7A11 (p = 1.19×10-150) and was previously implicated in other alcohol MWASs. In the cell-type specific results, the top finding was in PDIA5 in CD8+ naïve T-cells (p = 2.83×10-12). Whole blood and cell-type specific findings tended to show significant overlap with genome-wide association studies of problematic alcohol use but not those based on alcohol consumption. In summary, we observed considerable overlap with previous alcohol MWASs and GWASs suggesting robust associations. Further, our novel DNAm findings, such as the involvement of Rho GTPase pathways, implicate new therapeutic targets that warrant further investigation. Due to the large number of findings in whole blood and coordinated changes across cell-types, we hypothesize results may capture alcohol exposure effects. Future work should use novel design to disentangle exposure versus liability effects.
- Open Access
- 24 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Insights from a methylome-wide association study of antidepressant exposure
This study tests the association of whole-blood DNA methylation and antidepressant exposure in 16,531 individuals from Generation Scotland (GS), using self-report and prescription-derived measures. We identify 8 associations and a high concordance of results between self-report and prescription-derived measures. Sex-stratified analyses observe nominally significant increased effect estimates in females for four CpGs. There is observed enrichment for genes expressed in the Amygdala and annotated to synaptic vesicle membrane ontology. Two CpGs (cg15071067; DGUOK-AS1 and cg26277237; KANK1) show correlation between DNA methylation with the time in treatment. There is a significant overlap in the top 1% of CpGs with another independent methylome-wide association study of antidepressant exposure. Finally, a methylation profile score trained on this sample shows a significant association with antidepressant exposure in a meta-analysis of eight independent external datasets. In this large investigation of antidepressant exposure and DNA methylation, we demonstrate robust associations which warrant further investigation to inform on the design of more effective and tolerated treatments for depression.
- 24 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessInsights from a methylome-wide association study of antidepressant exposure
This study tests the association of whole-blood DNA methylation and antidepressant exposure in 16,531 individuals from Generation Scotland (GS), using self-report and prescription-derived measures. We identify 8 associations and a high concordance of results between self-report and prescription-derived measures. Sex-stratified analyses observe nominally significant increased effect estimates in females for four CpGs. There is observed enrichment for genes expressed in the Amygdala and annotated to synaptic vesicle membrane ontology. Two CpGs (cg15071067; DGUOK-AS1 and cg26277237; KANK1) show correlation between DNA methylation with the time in treatment. There is a significant overlap in the top 1% of CpGs with another independent methylome-wide association study of antidepressant exposure. Finally, a methylation profile score trained on this sample shows a significant association with antidepressant exposure in a meta-analysis of eight independent external datasets. In this large investigation of antidepressant exposure and DNA methylation, we demonstrate robust associations which warrant further investigation to inform on the design of more effective and tolerated treatments for depression.
- Open Access
- 1 September 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (12) , 3398-3406
Lagged effects of childhood depressive symptoms on adult epigenetic aging
Background: Cross-sectional studies have identified health risks associated with epigenetic aging. However, it is unclear whether these risks make epigenetic clocks ‘tick faster’ (i.e. accelerate biological aging). The current study examines concurrent and lagged within-person changes of a variety of health risks associated with epigenetic aging.Methods: Individuals from the Great Smoky Mountains Study were followed from age 9 to 35 years. DNA methylation profiles were assessed from blood, at multiple timepoints (i.e. waves) for each individual. Health risks were psychiatric, lifestyle, and adversity factors. Concurrent (N = 539 individuals; 1029 assessments) and lagged (N = 380 individuals; 760 assessments) analyses were used to determine the link between health risks and epigenetic aging.Results: Concurrent models showed that BMI (r = 0.15, PFDR < 0.01) was significantly correlated to epigenetic aging at the subject-level but not wave-level. Lagged models demonstrated that depressive symptoms (b = 1.67 months per symptom, PFDR = 0.02) in adolescence accelerated epigenetic aging in adulthood, also when models were fully adjusted for BMI, smoking, and cannabis and alcohol use.Conclusions: Within-persons, changes in health risks were unaccompanied by concurrent changes in epigenetic aging, suggesting that it is unlikely for risks to immediately ‘accelerate’ epigenetic aging. However, time lagged analyses indicated that depressive symptoms in childhood/adolescence predicted epigenetic aging in adulthood. Together, findings suggest that age-related biological embedding of depressive symptoms is not instant but provides prognostic opportunities. Repeated measurements and longer follow-up times are needed to examine stable and dynamic contributions of childhood experiences to epigenetic aging across the lifespan.
- 1 September 2024
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 54 (12) , 3398-3406
Open AccessLagged effects of childhood depressive symptoms on adult epigenetic aging
Background: Cross-sectional studies have identified health risks associated with epigenetic aging. However, it is unclear whether these risks make epigenetic clocks ‘tick faster’ (i.e. accelerate biological aging). The current study examines concurrent and lagged within-person changes of a variety of health risks associated with epigenetic aging.Methods: Individuals from the Great Smoky Mountains Study were followed from age 9 to 35 years. DNA methylation profiles were assessed from blood, at multiple timepoints (i.e. waves) for each individual. Health risks were psychiatric, lifestyle, and adversity factors. Concurrent (N = 539 individuals; 1029 assessments) and lagged (N = 380 individuals; 760 assessments) analyses were used to determine the link between health risks and epigenetic aging.Results: Concurrent models showed that BMI (r = 0.15, PFDR < 0.01) was significantly correlated to epigenetic aging at the subject-level but not wave-level. Lagged models demonstrated that depressive symptoms (b = 1.67 months per symptom, PFDR = 0.02) in adolescence accelerated epigenetic aging in adulthood, also when models were fully adjusted for BMI, smoking, and cannabis and alcohol use.Conclusions: Within-persons, changes in health risks were unaccompanied by concurrent changes in epigenetic aging, suggesting that it is unlikely for risks to immediately ‘accelerate’ epigenetic aging. However, time lagged analyses indicated that depressive symptoms in childhood/adolescence predicted epigenetic aging in adulthood. Together, findings suggest that age-related biological embedding of depressive symptoms is not instant but provides prognostic opportunities. Repeated measurements and longer follow-up times are needed to examine stable and dynamic contributions of childhood experiences to epigenetic aging across the lifespan.
- 20 August 2024
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (5) , 95
A Perspective on Evaluating Life Stage Differences in Drug Dosages for Drug Labeling and Instructions
Drug labeling and instructions provide essential information for patients regarding the usage of drugs. Instructions for the dosage of drug usage are critical for the effectiveness of the drug and the safety of patients. The dosage of many drugs varies depending on the patient's age. However, as our understanding of human biology deepens, we believe that these instructions need to be modified to incorporate different life stages. This is because human biology and metabolism differ significantly among different life stages, and their responses to drugs also vary. Additionally, the same age of different persons may fall into different life stages. Therefore, our group from multiple institutes and countries proposes a reexamination of whether incorporating life stages in all or any drug instructions will greatly enhance drug efficiency and patients' health.
- 20 August 2024
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (5) , 95
A Perspective on Evaluating Life Stage Differences in Drug Dosages for Drug Labeling and Instructions
Drug labeling and instructions provide essential information for patients regarding the usage of drugs. Instructions for the dosage of drug usage are critical for the effectiveness of the drug and the safety of patients. The dosage of many drugs varies depending on the patient's age. However, as our understanding of human biology deepens, we believe that these instructions need to be modified to incorporate different life stages. This is because human biology and metabolism differ significantly among different life stages, and their responses to drugs also vary. Additionally, the same age of different persons may fall into different life stages. Therefore, our group from multiple institutes and countries proposes a reexamination of whether incorporating life stages in all or any drug instructions will greatly enhance drug efficiency and patients' health.
- Top Cited PapersOpen Access
- 16 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
PRC2-AgeIndex as a universal biomarker of aging and rejuvenation
DNA methylation (DNAm) is one of the most reliable biomarkers of aging across mammalian tissues. While the age-dependent global loss of DNAm has been well characterized, DNAm gain is less characterized. Studies have demonstrated that CpGs which gain methylation with age are enriched in Polycomb Repressive Complex 2 (PRC2) targets. However, whole-genome examination of all PRC2 targets as well as determination of the pan-tissue or tissue-specific nature of these associations is lacking. Here, we show that low-methylated regions (LMRs) which are highly bound by PRC2 in embryonic stem cells (PRC2 LMRs) gain methylation with age in all examined somatic mitotic cells. We estimated that this epigenetic change represents around 90% of the age-dependent DNAm gain genome-wide. Therefore, we propose the “PRC2-AgeIndex,” defined as the average DNAm in PRC2 LMRs, as a universal biomarker of cellular aging in somatic cells which can distinguish the effect of different anti-aging interventions.
- 16 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Top Cited PapersOpen AccessPRC2-AgeIndex as a universal biomarker of aging and rejuvenation
DNA methylation (DNAm) is one of the most reliable biomarkers of aging across mammalian tissues. While the age-dependent global loss of DNAm has been well characterized, DNAm gain is less characterized. Studies have demonstrated that CpGs which gain methylation with age are enriched in Polycomb Repressive Complex 2 (PRC2) targets. However, whole-genome examination of all PRC2 targets as well as determination of the pan-tissue or tissue-specific nature of these associations is lacking. Here, we show that low-methylated regions (LMRs) which are highly bound by PRC2 in embryonic stem cells (PRC2 LMRs) gain methylation with age in all examined somatic mitotic cells. We estimated that this epigenetic change represents around 90% of the age-dependent DNAm gain genome-wide. Therefore, we propose the “PRC2-AgeIndex,” defined as the average DNAm in PRC2 LMRs, as a universal biomarker of cellular aging in somatic cells which can distinguish the effect of different anti-aging interventions.
- Open Access
Antidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association Study
Importance: Understanding antidepressant mechanisms could help design more effective and tolerated treatments. Objective: Identify DNA methylation (DNAm) changes associated with antidepressant exposure. Design: Case-control methylome-wide association studies (MWAS) of antidepressant exposure were performed from blood samples collected between 2006-2011 in Generation Scotland (GS). The summary statistics were tested for enrichment in specific tissues, gene ontologies and an independent MWAS in the Netherlands Study of Depression and Anxiety (NESDA). A methylation profile score (MPS) was derived and tested for its association with antidepressant exposure in eight independent cohorts, alongside prospective data from GS. Setting: Cohorts; GS, NESDA, FTC, SHIP-Trend, FOR2107, LBC1936, MARS-UniDep, ALSPAC, E-Risk, and NTR. Participants: Participants with DNAm data and self-report/prescription derived antidepressant exposure. Main Outcome(s) and Measure(s): Whole-blood DNAm levels were assayed by the EPIC/450K Illumina array (9 studies, N exposed = 661, N unexposed = 9,575) alongside MBD-Seq in NESDA (N exposed = 398, N unexposed = 414). Antidepressant exposure was measured by self- report and/or antidepressant prescriptions. Results: The self-report MWAS (N = 16,536, N exposed = 1,508, mean age = 48, 59% female) and the prescription-derived MWAS (N = 7,951, N exposed = 861, mean age = 47, 59% female), found hypermethylation at seven and four DNAm sites (p < 9.42x10 -8 ), respectively. The top locus was cg26277237 ( KANK1, p self-report = 9.3x10 -13 , p prescription = 6.1x10 -3 ). The self-report MWAS found a differentially methylated region, mapping to DGUOK-AS1 ( p adj = 5.0x10 -3 ) alongside significant enrichment for genes expressed in the amygdala, the “synaptic vesicle membrane” gene ontology and the top 1% of CpGs from the NESDA MWAS (OR = 1.39, p < 0.042). The MPS was associated with antidepressant exposure in meta-analysed data from external cohorts (N studies = 9, N = 10,236, N exposed = 661, f3 = 0.196, p < 1x10 -4 ). Conclusions and Relevance: Antidepressant exposure is associated with changes in DNAm across different cohorts. Further investigation into these changes could inform on new targets for antidepressant treatments. 3 Key Points: Question: Is antidepressant exposure associated with differential whole blood DNA methylation? Findings: In this methylome-wide association study of 16,536 adults across Scotland, antidepressant exposure was significantly associated with hypermethylation at CpGs mapping to KANK1 and DGUOK-AS1. A methylation profile score trained on this sample was significantly associated with antidepressant exposure (pooled f3 [95%CI]=0.196 [0.105, 0.288], p < 1x10 -4 ) in a meta-analysis of external datasets. Meaning: Antidepressant exposure is associated with hypermethylation at KANK1 and DGUOK-AS1 , which have roles in mitochondrial metabolism and neurite outgrowth. If replicated in future studies, targeting these genes could inform the design of more effective and better tolerated treatments for depression.
Open AccessAntidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association Study
Importance: Understanding antidepressant mechanisms could help design more effective and tolerated treatments. Objective: Identify DNA methylation (DNAm) changes associated with antidepressant exposure. Design: Case-control methylome-wide association studies (MWAS) of antidepressant exposure were performed from blood samples collected between 2006-2011 in Generation Scotland (GS). The summary statistics were tested for enrichment in specific tissues, gene ontologies and an independent MWAS in the Netherlands Study of Depression and Anxiety (NESDA). A methylation profile score (MPS) was derived and tested for its association with antidepressant exposure in eight independent cohorts, alongside prospective data from GS. Setting: Cohorts; GS, NESDA, FTC, SHIP-Trend, FOR2107, LBC1936, MARS-UniDep, ALSPAC, E-Risk, and NTR. Participants: Participants with DNAm data and self-report/prescription derived antidepressant exposure. Main Outcome(s) and Measure(s): Whole-blood DNAm levels were assayed by the EPIC/450K Illumina array (9 studies, N exposed = 661, N unexposed = 9,575) alongside MBD-Seq in NESDA (N exposed = 398, N unexposed = 414). Antidepressant exposure was measured by self- report and/or antidepressant prescriptions. Results: The self-report MWAS (N = 16,536, N exposed = 1,508, mean age = 48, 59% female) and the prescription-derived MWAS (N = 7,951, N exposed = 861, mean age = 47, 59% female), found hypermethylation at seven and four DNAm sites (p < 9.42x10 -8 ), respectively. The top locus was cg26277237 ( KANK1, p self-report = 9.3x10 -13 , p prescription = 6.1x10 -3 ). The self-report MWAS found a differentially methylated region, mapping to DGUOK-AS1 ( p adj = 5.0x10 -3 ) alongside significant enrichment for genes expressed in the amygdala, the “synaptic vesicle membrane” gene ontology and the top 1% of CpGs from the NESDA MWAS (OR = 1.39, p < 0.042). The MPS was associated with antidepressant exposure in meta-analysed data from external cohorts (N studies = 9, N = 10,236, N exposed = 661, f3 = 0.196, p < 1x10 -4 ). Conclusions and Relevance: Antidepressant exposure is associated with changes in DNAm across different cohorts. Further investigation into these changes could inform on new targets for antidepressant treatments. 3 Key Points: Question: Is antidepressant exposure associated with differential whole blood DNA methylation? Findings: In this methylome-wide association study of 16,536 adults across Scotland, antidepressant exposure was significantly associated with hypermethylation at CpGs mapping to KANK1 and DGUOK-AS1. A methylation profile score trained on this sample was significantly associated with antidepressant exposure (pooled f3 [95%CI]=0.196 [0.105, 0.288], p < 1x10 -4 ) in a meta-analysis of external datasets. Meaning: Antidepressant exposure is associated with hypermethylation at KANK1 and DGUOK-AS1 , which have roles in mitochondrial metabolism and neurite outgrowth. If replicated in future studies, targeting these genes could inform the design of more effective and better tolerated treatments for depression.
- Open Access
Alcohol Use Disorder-Associated DNA Methylation in the Nucleus Accumbens and Dorsolateral Prefrontal Cortex
Background Alcohol use disorder (AUD) has a profound public health impact. However, understanding of the molecular mechanisms underlying the development and progression of AUD remain limited. Here, we interrogate AUD-associated DNA methylation (DNAm) changes within and across addiction-relevant brain regions: the nucleus accumbens (NAc) and dorsolateral prefrontal cortex (DLPFC). Methods Illumina HumanMethylation EPIC array data from 119 decedents of European ancestry (61 cases, 58 controls) were analyzed using robust linear regression, with adjustment for technical and biological variables. Associations were characterized using integrative analyses of public gene regulatory data and published genetic and epigenetic studies. We additionally tested for brain region-shared and -specific associations using mixed effects modeling and assessed implications of these results using public gene expression data. Results At a false discovery rate ≤ 0.05, we identified 53 CpGs significantly associated with AUD status for NAc and 31 CpGs for DLPFC. In a meta-analysis across the regions, we identified an additional 21 CpGs associated with AUD, for a total of 105 unique AUD-associated CpGs (120 genes). AUD-associated CpGs were enriched in histone marks that tag active promoters and our strongest signals were specific to a single brain region. Of the 120 genes, 23 overlapped with previous genetic associations for substance use behaviors; all others represent novel associations. Conclusions Our findings identify AUD-associated methylation signals, the majority of which are specific within NAc or DLPFC. Some signals may constitute predisposing genetic and epigenetic variation, though more work is needed to further disentangle the neurobiological gene regulatory differences associated with AUD.
Open AccessAlcohol Use Disorder-Associated DNA Methylation in the Nucleus Accumbens and Dorsolateral Prefrontal Cortex
Background Alcohol use disorder (AUD) has a profound public health impact. However, understanding of the molecular mechanisms underlying the development and progression of AUD remain limited. Here, we interrogate AUD-associated DNA methylation (DNAm) changes within and across addiction-relevant brain regions: the nucleus accumbens (NAc) and dorsolateral prefrontal cortex (DLPFC). Methods Illumina HumanMethylation EPIC array data from 119 decedents of European ancestry (61 cases, 58 controls) were analyzed using robust linear regression, with adjustment for technical and biological variables. Associations were characterized using integrative analyses of public gene regulatory data and published genetic and epigenetic studies. We additionally tested for brain region-shared and -specific associations using mixed effects modeling and assessed implications of these results using public gene expression data. Results At a false discovery rate ≤ 0.05, we identified 53 CpGs significantly associated with AUD status for NAc and 31 CpGs for DLPFC. In a meta-analysis across the regions, we identified an additional 21 CpGs associated with AUD, for a total of 105 unique AUD-associated CpGs (120 genes). AUD-associated CpGs were enriched in histone marks that tag active promoters and our strongest signals were specific to a single brain region. Of the 120 genes, 23 overlapped with previous genetic associations for substance use behaviors; all others represent novel associations. Conclusions Our findings identify AUD-associated methylation signals, the majority of which are specific within NAc or DLPFC. Some signals may constitute predisposing genetic and epigenetic variation, though more work is needed to further disentangle the neurobiological gene regulatory differences associated with AUD.
- Top Cited PapersOpen Access
- 1 December 2023
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 180 (12) , 884-895
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression
Objective: Postpartum depression (PPD) is a common subtype of major depressive disorder (MDD) that is more heritable, yet is understudied in psychiatric genetics. The authors conducted meta-analyses of genome-wide association studies (GWASs) to investigate the genetic architecture of PPD. Method: Meta-analyses were conducted on 18 cohorts of European ancestry (17,339 PPD cases and 53,426 controls), one cohort of East Asian ancestry (975 cases and 3,780 controls), and one cohort of African ancestry (456 cases and 1,255 controls), totaling 18,770 PPD cases and 58,461 controls. Post-GWAS analyses included 1) single-nucleotide polymorphism (SNP)–based heritability , 2) genetic correlations between PPD and other phenotypes, and 3) enrichment of the PPD GWAS findings in 27 human tissues and 265 cell types from the mouse central and peripheral nervous system. Results: No SNP achieved genome-wide significance in the European or the trans-ancestry meta-analyses. The of PPD was 0.14 (SE=0.02). Significant genetic correlations were estimated for PPD with MDD, bipolar disorder, anxiety disorders, posttraumatic stress disorder, insomnia, age at menarche, and polycystic ovary syndrome. Cell-type enrichment analyses implicate inhibitory neurons in the thalamus and cholinergic neurons within septal nuclei of the hypothalamus, a pattern that differs from MDD. Conclusions: While more samples are needed to reach genome-wide levels of significance, the results presented confirm PPD as a polygenic and heritable phenotype. There is also evidence that despite a high correlation with MDD, PPD may have unique genetic components. Cell enrichment results suggest GABAergic neurons, which converge on a common mechanism with the only medication approved by the U.S. Food and Drug Administration for PPD (brexanolone).
- 1 December 2023
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 180 (12) , 884-895
Top Cited PapersOpen AccessMeta-Analyses of Genome-Wide Association Studies for Postpartum Depression
Objective: Postpartum depression (PPD) is a common subtype of major depressive disorder (MDD) that is more heritable, yet is understudied in psychiatric genetics. The authors conducted meta-analyses of genome-wide association studies (GWASs) to investigate the genetic architecture of PPD. Method: Meta-analyses were conducted on 18 cohorts of European ancestry (17,339 PPD cases and 53,426 controls), one cohort of East Asian ancestry (975 cases and 3,780 controls), and one cohort of African ancestry (456 cases and 1,255 controls), totaling 18,770 PPD cases and 58,461 controls. Post-GWAS analyses included 1) single-nucleotide polymorphism (SNP)–based heritability , 2) genetic correlations between PPD and other phenotypes, and 3) enrichment of the PPD GWAS findings in 27 human tissues and 265 cell types from the mouse central and peripheral nervous system. Results: No SNP achieved genome-wide significance in the European or the trans-ancestry meta-analyses. The of PPD was 0.14 (SE=0.02). Significant genetic correlations were estimated for PPD with MDD, bipolar disorder, anxiety disorders, posttraumatic stress disorder, insomnia, age at menarche, and polycystic ovary syndrome. Cell-type enrichment analyses implicate inhibitory neurons in the thalamus and cholinergic neurons within septal nuclei of the hypothalamus, a pattern that differs from MDD. Conclusions: While more samples are needed to reach genome-wide levels of significance, the results presented confirm PPD as a polygenic and heritable phenotype. There is also evidence that despite a high correlation with MDD, PPD may have unique genetic components. Cell enrichment results suggest GABAergic neurons, which converge on a common mechanism with the only medication approved by the U.S. Food and Drug Administration for PPD (brexanolone).